Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma

Abstract

BackgroundBone marrow biopsy is considered essential for the staging and risk-adapted treatment of Hodgkin's lymphoma with unfavorable risk features. We reviewed the cases of pediatric Hodgkin's lymphoma in our institution to determine the impact of bone marrow involvement on treatment, relapse, and survival. Design and MethodsWe reviewed the clinical characteristics and outcome of 383 patients treated for Hodgkin's lymphoma at St. Jude Children's Research Hospital between August 1990 and August 2008. The 5-year survival estimates for patients with and without bone marrow involvement were compared. ResultsOf 228 patients who had a bone marrow biopsy at diagnosis, 21 had bone marrow involvement. Bone marrow findings changed the disease stage in only seven patients (3.1%): from IB to IVB (n=1), from IIA (with bulky disease) to IVA (n=1), from IIB to IVB (n=1), and from IIIB to IVB (n=4). One patient's risk assignment changed from intermediate to unfavorable risk without his chemotherapy being altered. No statistically significant difference was observed between patients with stage IV Hodgkin's lymphoma who did (n=21) and did not (n=61) have bone marrow involvement in 5-year relapse-free survival (89.6± 7% versus 73.9±6.1%; P=0.25) or 5-year overall survival (95.2±8.2% versus 87.3±4.9%; P=0.82). ConclusionsAlthough bone marrow involvement changed the stage in 3.1% of pediatric Hodgkin's lymphoma patients, it did not change risk-adapted treatment or prognosis. We conclude that bone marrow biopsy need not be performed at diagnosis in patients who have unfavorable risk features, although this finding should be confirmed by larger prospective studies.Key words: bone marrow, risk features, Hodgkin's lymphoma. 's lymphoma. Haematologica 2010;95(10):1691-1696. doi:10.3324/haematol.2010 This is an open-access paper. © F e r r a t a S t o r t i F o u n d a t i o n Citation: Hines-Thomas MR, Howard SC, Hudson MM, Krasin MJ, Kaste SC, Shulkin BL, and Metzger ML. Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma

Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome

“…Bone marrow involvement in HL is rare, and it probably does not have a major impact on the treatment and outcome of patients. 19 Mixed cellularity was the most common histologic subtype (45%) in this cohort and this has not changed substantially compared with the previous study and as observed in other studies from India. 3 - 10 Nodular sclerosis is a more common histologic subtype in developed countries.…”

Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

“…This is one of the largest studies to compare WB‐MRI, FDG‐PET/CT, and BMB in lymphomas, but has some limitations. First, it would be useful to study a larger sample of patients with HL, which carries a low risk of BMI . Marginal zone and mantle cell lymphomas, even if they carry a higher risk of BMI, were under‐represented sub‐populations in our study.…”

Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa

“…Although this study protocol encouraged bone marrow biopsy for all patients, it is no longer required in settings that have PET‐CT facilities available 21 . Unfortunately, most African countries do not have access to this diagnostic modality and thus should continue to perform bone marrow biopsies, especially in patients with suspected late‐stage disease.…”